Seelos Therapeutics (SEEL) Stock Price & Analysis

SEEL$0.37—
Biotechnology
Compare
Market cap—Enterprise value$11.45MRevenue (TTM)$2.01MMarket position—

AI Analysis

Snapshot

Seelos Therapeutics (SEEL) trades at $0.37, with a trailing P/E of n/a. This snapshot uses the price and valuation already on the page. It is a description of the reported figures, not a recommendation.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

…
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

…
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

…
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Seelos Therapeutics, Inc. (SEEL) last printed $0.37. Equity value is —. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2014201520162017201820192020202120222023
$9.26M$4.84M$5.76M$0.00$0.00$375,000.00$0.00$0.00$0.00$2.2M

About

Seelos Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the discovery, development, and eventual commercialization of innovative therapies. These treatments primarily target central nervous system (CNS), respiratory, and various other medical conditions. The company's pipeline includes several key clinical-stage candidates. Foremost among these is SLS-002, an intranasally administered racemic ketamine, being investigated for rapidly alleviating acute suicidal ideation and behavior in individuals with major depressive disorder (MDD). Another significant program, SLS-005, acts as a protein stabilizer, addressing amyotrophic lateral sclerosis (ALS) and Sanfilippo syndrome. Additionally, SLS-006 is a partial dopamine agonist under development for the treatment of Parkinson's disease (PD). Beyond its clinical efforts, Seelos maintains a robust preclinical portfolio exploring novel mechanisms. This includes SLS-007, an anti-alpha-synuclein peptidic inhibitor designed to combat Parkinson's disease, and SLS-008, an orally bioavailable antagonist targeting chemoattractant receptor-homologous molecule, intended for chronic inflammatory conditions such as asthma and specific pediatric orphan diseases. Other early-stage candidates comprise SLS-004 for Parkinson's disease; SLS-010, an oral histamine H3A receptor antagonist aimed at narcolepsy and related sleep disorders; and SLS-012, an injectable formulation for managing post-operative pain. Founded in 1987, Seelos Therapeutics, Inc. operates from its headquarters situated in New York, New York.

Seelos Therapeutics (SEEL) Stock Price & Analysis

SEEL price $0.37 —

Ticker
SEEL
Price
$0.37
Change
—
Dividend yield
0.00%
Sector
Healthcare
Industry
Biotechnology

Insights · Forecast · Financials · Learn

Stocklytics home · Screener